IBRX•benzinga•
ImmunityBio Q4 2024 GAAP EPS $(0.09) Beats $(0.20) Estimate, Sales $7.55M Miss $7.82M Estimate, Cash And Cash Equivalents, And Marketable Securities Of $149.8M
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 3, 2025 by benzinga